NO20033921L - Inhibitor av monoaminopptak - Google Patents

Inhibitor av monoaminopptak

Info

Publication number
NO20033921L
NO20033921L NO20033921A NO20033921A NO20033921L NO 20033921 L NO20033921 L NO 20033921L NO 20033921 A NO20033921 A NO 20033921A NO 20033921 A NO20033921 A NO 20033921A NO 20033921 L NO20033921 L NO 20033921L
Authority
NO
Norway
Prior art keywords
monoamine uptake
uptake inhibitor
monoamine
inhibitor
methods
Prior art date
Application number
NO20033921A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033921D0 (no
Inventor
Edward Louis Mattiuz
John-Michael Sauer
William Joe Wheeler
David Taiwai Wong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033921(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20033921D0 publication Critical patent/NO20033921D0/no
Publication of NO20033921L publication Critical patent/NO20033921L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20033921A 2001-03-06 2003-09-04 Inhibitor av monoaminopptak NO20033921L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (2)

Publication Number Publication Date
NO20033921D0 NO20033921D0 (no) 2003-09-04
NO20033921L true NO20033921L (no) 2003-11-05

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033921A NO20033921L (no) 2001-03-06 2003-09-04 Inhibitor av monoaminopptak

Country Status (35)

Country Link
US (2) US20040082666A1 (hu)
EP (1) EP1379492B1 (hu)
JP (1) JP2004525912A (hu)
KR (1) KR20030092012A (hu)
CN (1) CN1229331C (hu)
AP (1) AP2003002855A0 (hu)
AT (2) ATE396170T1 (hu)
AU (1) AU2002245385B2 (hu)
BR (1) BR0207716A (hu)
CA (1) CA2440161A1 (hu)
CH (1) CH695982A5 (hu)
CZ (1) CZ20032380A3 (hu)
DE (1) DE60226715D1 (hu)
DK (1) DK200301267A (hu)
EA (1) EA005768B1 (hu)
EC (1) ECSP034760A (hu)
EE (1) EE200300419A (hu)
ES (2) ES2201942B2 (hu)
FI (1) FI20031191A (hu)
GB (1) GB2389851B (hu)
HR (1) HRP20030710A2 (hu)
HU (1) HUP0303341A3 (hu)
IL (1) IL157779A0 (hu)
LT (1) LT5143B (hu)
LU (1) LU91038B1 (hu)
LV (1) LV13119B (hu)
NO (1) NO20033921L (hu)
NZ (1) NZ527431A (hu)
OA (1) OA12494A (hu)
PL (1) PL363840A1 (hu)
SE (1) SE526598C2 (hu)
SK (1) SK10632003A3 (hu)
TR (1) TR200705146T1 (hu)
WO (1) WO2002070457A1 (hu)
ZA (1) ZA200306882B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070457A1 (en) * 2001-03-06 2002-09-12 Eli Lilly And Company Inhibitor of monoamine uptake
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
CN112930179A (zh) * 2018-10-31 2021-06-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ES2249256T3 (es) 1999-04-09 2006-04-01 Eli Lilly And Company Procedimientos de preparacion de 3-ariloxi-3-arilpropilamidas y sus intermedios.
BR0115301A (pt) * 2000-11-15 2004-12-14 Lilly Co Eli Uso de um inibidor seletivo da recaptação de norepinefrina
WO2002070457A1 (en) * 2001-03-06 2002-09-12 Eli Lilly And Company Inhibitor of monoamine uptake

Also Published As

Publication number Publication date
DE60226715D1 (de) 2008-07-03
EA005768B1 (ru) 2005-06-30
CN1229331C (zh) 2005-11-30
ES2201942A1 (es) 2004-03-16
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
EP1379492B1 (en) 2008-05-21
ZA200306882B (en) 2004-12-03
WO2002070457A1 (en) 2002-09-12
GB2389851A (en) 2003-12-24
FI20031191A (fi) 2003-08-25
OA12494A (en) 2006-05-24
LU91038B1 (fr) 2003-09-11
ES2305221T3 (es) 2008-11-01
LT2003075A (en) 2004-03-25
EE200300419A (et) 2004-02-16
IL157779A0 (en) 2004-03-28
DK200301267A (da) 2003-11-06
ES2201942B2 (es) 2004-12-16
SE0302361D0 (sv) 2003-09-03
US20050209341A1 (en) 2005-09-22
KR20030092012A (ko) 2003-12-03
CH695982A5 (de) 2006-11-15
LT5143B (lt) 2004-06-25
ATE396170T1 (de) 2008-06-15
SK10632003A3 (sk) 2004-06-08
AU2002245385B2 (en) 2007-01-18
LV13119B (en) 2004-06-20
EP1379492A1 (en) 2004-01-14
CN1494526A (zh) 2004-05-05
GB0323169D0 (en) 2003-11-05
NO20033921D0 (no) 2003-09-04
US20040082666A1 (en) 2004-04-29
PL363840A1 (en) 2004-11-29
US7384983B2 (en) 2008-06-10
SE0302361L (sv) 2003-09-03
AP2003002855A0 (en) 2003-08-20
SE526598C2 (sv) 2005-10-18
ECSP034760A (es) 2003-10-28
WO2002070457A8 (en) 2004-06-03
JP2004525912A (ja) 2004-08-26
AT414238B (de) 2006-10-15
BR0207716A (pt) 2004-03-23
CZ20032380A3 (en) 2004-03-17
EA200300978A1 (ru) 2004-02-26
NZ527431A (en) 2005-05-27
HUP0303341A2 (hu) 2004-01-28
GB2389851B (en) 2005-05-25
ATA90422002A (de) 2006-01-15
TR200705146T1 (tr) 2008-02-21
CA2440161A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
CY2015028I1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60234125D1 (de) E inhibitoren
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
MY136892A (en) Deacetylase inhibitors
PT1370553E (pt) Inibidores de rhoquinase
SG160211A1 (en) Pi-3 kinase inhibitor prodrugs
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
NO20026282D0 (no) Inhibitorer for kopper-inneholdende amin oksidase
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
DE60007095T2 (de) Calanolide zur hemmung von btk
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
ATE353320T1 (de) Tricyclische proteinkinasehemmer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DE60125429D1 (de) Zolpidem hemitartrat solvat
DE60229420D1 (de) Neue metallproteinaseinhibitoren
SE0301650D0 (sv) Novel compounds
NO20033921L (no) Inhibitor av monoaminopptak
DE60207833D1 (de) Peptiddeformylase-hemmer
DK1144348T3 (da) LTA4-hydrolaseinhibitorer
DE60232650D1 (de) Peptiddeformylaseinhibitoren
DE60207384D1 (de) Peptid-deformylase-hemmer
ATE364037T1 (de) Tryptasehemmer
DOP2002000329A (es) Composicion solida
HN2000000084A (es) Inhibidores de metaloproteasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application